Clinical trial · Observational

Biomarkers in Blood Samples From Patients With Refractory Non-Small Cell Lung Cancer Previously Treated With Sorafenib Tosylate

BRAF, KRAS and EGFR Mutation Detection in Non-Small Cell Lung Cancer Patients Treated With Sorafenib Monotherapy

NCT01124669CI-TRIAL-00027616completedClinicalTrials.gov clinicaltrialsPublishedExplore in graph →

Summary

Brief summary (as posted)

RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. PURPOSE: This research study is studying biomarkers in blood samples from patients with refractory non-small cell lung cancer previously treated with sorafenib tosylate.

Conditions

Conditions (1)

Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.

Condition (as posted)	Mapped entity	Match	Confidence
Lung Cancer	Malignant Lung Neoplasm	CURATED_EXACT	0.92

Interventions

Interventions (3)

Intervention	Type	Mapped drug	Match
DNA analysis	Genetic	—	UNRESOLVED
laboratory biomarker analysis	Other	—	UNRESOLVED
mutation analysis	Genetic	—	UNRESOLVED

Design

Arms and outcomes

Arms (0)

[]

Primary outcomes (2)

measure
Mutation rate of sorafenib tosylate-target gene BRAF, and its upstream proteins KRAS and EGFR
timeFrame
1 mont
measure
Association between BRAF, KRAS, and EGFR mutation status and clinical benefits (stable disease or partial response)
timeFrame
1 month

Eligibility

Eligibility (as posted)

Sex: All
Minimum age: 18 Years
Maximum age: 120 Years

Show eligibility criteria text

DISEASE CHARACTERISTICS:

* Diagnosis of refractory non-small cell lung cancer
* Received sorafenib tosylate on protocol ECOG-E2501
* Available blood specimens

PATIENT CHARACTERISTICS:

* Not specified

PRIOR CONCURRENT THERAPY:

* See Disease Characteristics

References

Publications (0)

Data not yet available

No reference posted for this study.